MBX Biosciences, Inc. (MBX) Price & Analysis

Compare

152 Followers

MBX Stock Chart & Stats

$13.22

-$0.30(-2.05%)

At close: Jan 08 4:00 PM EST

$13.22

-$0.30(-2.05%)

Day’s Range― - ―

52-Week Range$4.81 - $27.50

Previous CloseN/A

Volume52.29K

Average Volume (3M)2.04M

Market Cap

$615.73M

Enterprise Value$157.38M

Total Cash (Recent Filing)$224.91M

Total Debt (Recent Filing)$650.00K

Price to Earnings (P/E)―

Beta2.01

Next Earnings

Nov 06, 2025

EPS Estimate

-0.7

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.58

Shares Outstanding44,715,500

10 Day Avg. Volume1,024,037

30 Day Avg. Volume2,039,426

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.26

Enterprise Value/Revenue708.93

Enterprise Value/Gross Profit-948.09

Enterprise Value/Ebitda-1.78

Forecast

1Y Price Target

$52.14

Price Target Upside294.40% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering7

Bulls Say, Bears Say

Bulls Say

Clinical Trial OutcomesThe canvuparatide Phase 2 Avail trial is expected to achieve a clinically meaningful placebo-adjusted response rate of ~48%, which is seen as positive by key opinion leaders.

Market PotentialThe lead asset canvuparatide (MBX 2109) has significant global peak potential due to its differentiating weekly dosing in the emerging parathyroid hormone replacement market for hypoparathyroidism.

Bears Say

Clinical Trial RisksRisks include: 1) Clinical trial risk with lack of durability; 2) Unexpected safety concerns seen with drugs in ongoing clinical trials.

Financial RisksRisks include: 3) Cash need and dilution risk.

MBX Biosciences, Inc. News

3 Best Stocks to Buy Now, 10/16/2025, According to Top Analysts

Which stocks are best to buy now? According to Top Wall Street Analysts, the three stocks listed below...

3d ago

CZR

MBX

MBX Biosciences initiated with a Buy at Truist

Truist analyst Srikripa Devarakonda initiated coverage of MBX Biosciences (MBX) with a Buy rating and $50 price target...

5d ago

MBX

MBX Biosciences director buys $12.0M in common stock

In a regulatory filing, MBX Biosciences (MBX) disclosed that its director Patrick Heron bought 667K shares of common...

18d ago

MBX

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: CEA Industries Inc (BNC)...

24d ago

BNC

MBX

MBX Biosciences 11.1M share Secondary priced at $18.00

The deal size was increased to 11.1M shares from 10.0M and priced below last closing price of $20.10....

24d ago

MBX

MBX Biosciences price target raised to $56 from $38 at Mizuho

Mizuho raised the firm’s price target on MBX Biosciences (MBX) to $56 from $38 and keeps an Outperform...

25d ago

MBX

Wedbush sees no threat to Ascendis’ Yorvipath from competitor data

Wedbush analyst Yun Zhong does not believe the Phase 2 top-line data that MBX Biosciences (MBX) announced from...

26d ago

MBX

ASND

MBX Biosciences files to sell 10M shares of common stock

J.P. Morgan, Jefferies, TD Cowen, Guggenheim, Citizens Capital, and Oppenheimer are acting as the underwriters for the offering....

27d ago

MBX

Morning News Wrap-Up: Monday’s Biggest Stock Market Stories!

Stocks are a hot topic on Monday and TipRanks’ is ready with a breakdown of the biggest headlines. ...

27d ago

AMD

DIA

MBX Biosciences price target raised to $61 from $38 at Citizens JMP

Citizens JMP raised the firm’s price target on MBX Biosciences (MBX) to $61 from $38 and keeps an...

27d ago

MBX

Pfizer to acquire Metsera, Oracle names new CEOs: Morning Buzz

The major averages were broadly higher near noon, adding to last week’s strong gains as investors weigh a...

27d ago

CCO

MBX Biosciences price target raised to $80 from $38 at Oppenheimer

Oppenheimer raised the firm’s price target on MBX Biosciences (MBX) to $80 from $38 and keeps an Outperform...

27d ago

MBX

ASND

MBX Biosciences Stock Rockets on Clinical Trial Update

MBX Biosciences stock climbed higher following the release of new clinical trial results. ...

27d ago

MBX

MBX Biosciences Announces Public Offering Agreement

An update from MBX Biosciences, Inc. ( ($MBX) ) is now available. On September 24, 2025, MBX Biosciences,...

23d ago

MBX

MBX FAQ

What was MBX Biosciences, Inc.’s price range in the past 12 months?

MBX Biosciences, Inc. lowest stock price was $4.81 and its highest was $27.50 in the past 12 months.

What is MBX Biosciences, Inc.’s market cap?

MBX Biosciences, Inc.’s market cap is $615.73M.

When is MBX Biosciences, Inc.’s upcoming earnings report date?

MBX Biosciences, Inc.’s upcoming earnings report date is Nov 06, 2025 which is in 18 days.

How were MBX Biosciences, Inc.’s earnings last quarter?

MBX Biosciences, Inc. released its earnings results on Aug 07, 2025. The company reported -$0.58 earnings per share for the quarter, beating the consensus estimate of -$0.735 by $0.155.

Is MBX Biosciences, Inc. overvalued?

According to Wall Street analysts MBX Biosciences, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does MBX Biosciences, Inc. pay dividends?

MBX Biosciences, Inc. does not currently pay dividends.

What is MBX Biosciences, Inc.’s EPS estimate?

MBX Biosciences, Inc.’s EPS estimate is -0.7.

How many shares outstanding does MBX Biosciences, Inc. have?

MBX Biosciences, Inc. has 44,715,500 shares outstanding.

What happened to MBX Biosciences, Inc.’s price movement after its last earnings report?

MBX Biosciences, Inc. reported an EPS of -$0.58 in its last earnings report, beating expectations of -$0.735. Following the earnings report the stock price went down -4.627%.

Which hedge fund is a major shareholder of MBX Biosciences, Inc.?

Currently, no hedge funds are holding shares in MBX

MBX Biosciences, Inc. Stock Smart Score

Outperform

Fundamentals

Return on Equity

-56.28%

Trailing 12-Months

Asset Growth

268.18%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

MBX Biosciences, Inc.

MBX Biosciences, Inc. (MBX) is a biotechnology company focused on the discovery and development of peptide therapeutics to address unmet needs in endocrine disorders. The company leverages its proprietary platform to create novel therapies aimed at improving the lives of patients with complex hormonal conditions. MBX's core products are in various stages of clinical development, targeting specific endocrine diseases where current treatment options are limited or inadequate.

MBX Biosciences, Inc. (MBX) Earnings & Revenues

Historic Earnings Reports

MBX Stock 12 Month Forecast

Average Price Target

$52.14

▲(294.40% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"$5","25":"$25","45":"$45","65":"$65","85":"$85"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":84,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$84.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":52.14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$52.14</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":36,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$36.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,25,45,65,85],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.9,22.98461538461538,28.069230769230767,33.15384615384615,38.238461538461536,43.32307692307692,48.4076923076923,53.49230769230769,58.57692307692307,63.661538461538456,68.74615384615385,73.83076923076922,78.91538461538461,{"y":84,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.9,20.533846153846152,23.167692307692306,25.801538461538463,28.435384615384613,31.06923076923077,33.70307692307692,36.33692307692308,38.970769230769235,41.604615384615386,44.238461538461536,46.87230769230769,49.50615384615385,{"y":52.14,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.9,19.29230769230769,20.684615384615384,22.076923076923077,23.46923076923077,24.861538461538462,26.253846153846155,27.646153846153844,29.03846153846154,30.43076923076923,31.823076923076925,33.215384615384615,34.607692307692304,{"y":36,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":24.06,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":24.06,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.46,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.43,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.01,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.6,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.86,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.28,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.14,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.61,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.75,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.57,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.9,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >